) was administered on d3, to cover the possibility of secondary bacterial infection, but was subsequently discontinued. Symptoms resolved in case A by d3 and in case B by d4 of admission. PCR testing of SARS-CoV-2 from nose and throat swabs taken daily was negative from d2 onwards in case A and from d5 in case B (throat swabs from this individual were negative throughout). There was no clinical indication for the use of experimental antiviral therapies. Patients were deisolated according to current PHE guidance, based on complete resolution of symptoms and two sequential negative respiratory PCR tests at least 24 h apart. Rooms were decontaminated with 0.1% hypochlorite followed by UV light treatment. The contact of these individuals remained asymptomatic throughout the 14 days incubation period but was isolated as a precaution and to be close to family These first cases of SARS-CoV-2 are informative for clinicians caring for suspected and confirmed cases in the UK and elsewhere. Reassuringly, illness in both individuals was relatively mild and short-lived, with no evidence of parenchymal lung disease (reflected by normal oxygenation and the absence of radiological infiltrates) or of the late-stage deterioration that has been reported in case series 9 , possibly due to the absence of comorbidities. Experimental antiviral therapeutic options for severe disease were not considered necessary given the mild clinical nature of the illness. Clinical illness correlated with the presence of viral RNA in upper airway samples ( Fig. 1 ) , with no evidence of prolonged asymptomatic shedding, although discordance between nose and throat samples in case B highlights the need to sample both areas. It was reasonably assumed that the source of infection in case B was close contact with symptomatic case A, given that the time from travel to China to onset of symptoms in case B was 22 days, although this cannot be proven. Based on this assumption, the period from exposure to disease onset appeared short, at approximately 48 h, consistent with recent reports of the incubation period of SARS-CoV-2 6 . Co-occurrence of respiratory viral infection, as we observed in case B with rhinovirus, has been described in the context of SARS-CoV-2 ( https://www.medrxiv.org/ content/10.1101/2020.02.12.20022327v1 ) as it has with many other respiratory viruses spread by similar routes, and may have contributed to the increased symptomatology in case B. Interestingly the partner of case A, who was a close household contact, remained asymptomatic throughout and had negative tests for SARSCoV-2 shedding. It will be of interest to investigate the serological responses in this individual to ascertain evidence of subclinical infection. Isolation, minimisation of contacts and use of appropriate PPE is a cornerstone of management of high consequence respiratory viral infection. In the cases reported here, PHE recommendations for PPE were followed 10 and there were no breeches in PPE or nosocomial transmission. This should provide reassurance to healthcare workers managing patients with suspected Covid-19 in the UK that current PPE is both feasible and effective.
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